Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy Nov 19, 2018 8:30am EST
Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress Nov 06, 2018 7:30am EST
Atara Biotherapeutics Announces Presentations Highlighting Robust Off-the-Shelf, Allogeneic T-Cell Immunotherapy Pipeline and Next-Generation CAR T Technologies at the 60th American Society of Hematology (ASH) Annual Meeting and European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2018 Nov 01, 2018 9:03am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 24, 2018 4:55pm EDT
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors Sep 11, 2018 8:00am EDT
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies Sep 06, 2018 7:30am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 06, 2018 4:50pm EDT
Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress Aug 01, 2018 8:00am EDT
